In part 1 we examined the massively misleading opening claim of the abstract of the new study “Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial” by Ryan et al, published in the journal naturemedicine, and we looked at the magnitude of the conflicts of the authors. Today I’ll dig into the rest of the study.